Drugs /

mapk inhibitor

Back to Drugs List

Overview

NCI Definition [1]:
Any substance that inhibits mitogen-activated protein kinase (MAPK), an enzyme that catalyzes the addition of a phosphate group to a protein in the cell proliferation signaling pathway in response to external stimuli. Inhibition of mitogen-activated protein kinase can result in the inhibition of cell proliferation.

Clinical Trials

View Clinical Trials for mapk inhibitor

Mapk inhibitor has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating mapk inhibitor, 1 is phase 1 (1 open).

Malignant solid tumor is the most common disease being investigated in mapk inhibitor clinical trials [2].

Drug Details

Synonyms [2]:
mitogen-activated protein kinase inhibitor, mapk inhibitors
Drug Target(s) [2]:
MAPK1, MAPK10, MAPK11, MAPK12, MAPK13, MAPK14, MAPK3, MAPK6, MAPK7, MAPK8, MAPK9, MAPKAPK2
NCIT ID [1]:
C2149

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.